Zai Lab of Shanghai in-licensed global rights to two anti-inflammatory candidates from GlaxoSmithKline. Zai did not disclose many details about the assets, which target multiple anti-inflammatory indications, except to say that one is in a Phase II trial and the other in pre-clinical development. Zai’s rights to the drugs include global commercialization. Zai already has two other molecules for anti-inflammation in clinical development, one targets asthma/COPD, the other targets graft-versus-host/irritable bowel syndrome.
